Influence of Referral Pathway on Ebola Virus Disease Case-Fatality Rate and Effect of Survival Selection Bias
, Mads Damkjær, Suzanne Lunding, Kenn Dornonville de la Cour, Alyssa Young, Tim Brooks, Tom Sesay, Alex P. Salam, Sharmistha Mishra, and Merete Storgaard
Author affiliations: Aarhus University Hospital, Skejby, Denmark (F. Rudolf, M. Storgaard); GOAL Global, Port Loko, Sierra Leone (M. Damkjær, S. Lunding, K.D. de la Cour, A. Young, A.P. Salam, M. Storgaard); Danish Armed Forces Health Services, Brabrand, Denmark (F. Rudolf, M. Damkjær, S. Lunding, K.D. de la Cour, M. Storgaard); Hans Christian Andersen Children’s Hospital, Odense, Denmark (M. Damkjær); Copenhagen University Hospital, Hillerod, Denmark (S. Lunding); Odense University Hospital, Odense (K.D. de la Cour); GOAL Global, Freetown, Sierra Leone (A. Young); Public Health England, Salisbury, UK (T. Brooks); Sierra Leone Ministry of Health and Sanitation, Freetown (T. Sesay); Wohl King’s College Clinical Neuroscience Institute, London, UK (A.P. Salam); University of Toronto St. Michael’s Hospital, Toronto, Ontario, Canada (S. Mishra)
Figure. Kaplan-Meier survival plot stratified by referral pathway for patients admitted directly to an Ebola treatment center (ETC) with confirmed Ebola virus disease (cohort 1, blue line) and for patients diagnosed at the ETC (cohort 2, red line). Plots show the percentage of patients surviving as a function of time (days) from reported symptom onset. Shaded areas indicate 95% CIs. *p<0.05.
Page created: March 16, 2017
Page updated: March 16, 2017
Page reviewed: March 16, 2017
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.